LTRN
Lantern Pharma Inc
NASDAQ: LTRN · HEALTHCARE · BIOTECHNOLOGY
$2.05
+3.54% today
Updated 2026-04-30
Market cap
$27.69M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.57
Dividend yield
—
52W range
$1 – $6
Volume
0.7M
Lantern Pharma Inc (LTRN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | $-2544.00 | $1627.00 | $3388.00 | $97421.00 | $154681.00 | $174843.00 | $190493.00 | $17280.00 |
| Gross profit | $2544.00 | $-1627.00 | $-3388.00 | $-97421.00 | $-154681.00 | $-174843.00 | $-190493.00 | $-17280.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $572095.00 | $953185.00 | $2.24M | $7.57M | $8.60M | $11.89M | $16.13M | $11.51B |
| SG&A | $1.15M | $1.48M | $3.66M | $5.02M | $5.83M | $5.98M | $6.09M | $6.46B |
| Operating income | $-1.73M | $-2.43M | $-5.91M | $-12.59M | $-14.43M | $-17.88M | $-22.22M | $-17.98M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-1.73M | $-2.43M | $-5.90M | $-12.58M | $-14.42M | $-15.79M | $-22.20M | $-17.96M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-1.73M | $-2.43M | $-5.91M | $-12.59M | $-14.43M | $-15.96M | $-22.22M | $-17.98M |
| Interest expense | $0.00 | $0.00 | $0.00 | $221718.00 | $204355.00 | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-1.73M | $-2.43M | $-5.91M | $-12.36M | $-14.26M | $-15.96M | $-20.78M | $-17.12M |
| Net income growth (YoY) | — | -40.6% | -143.3% | -109.3% | -15.3% | -11.9% | -30.2% | +17.6% |
| Profit margin | — | — | — | — | — | — | — | — |